Clinical Trial: PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07511036) titled 'PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma' on March 31.

Brief Summary: This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naive patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.

Study Start Date: Sept. 01, 2026

Study Type: INTERVENTIONAL

Condition: Melanoma

Intervention: DRUG: Cemiplimab

Given by IV

DRUG: Lpilimumab

Given by IV

DRUG: Fianlimab

Given by IV

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderso...